Use Cases
Metabolic Health
Weight Loss and Liver Fat
The most common reason people look at peptides at all: sustained appetite reduction, and what trials report about liver fat alongside it.
BModerate Human EvidenceReviewed September 1, 2026
Compounds used for this goal
The reason
Why people use it
- Appetite and food preoccupation fall sharply on incretin agonists, which is the effect most people describe first — meals end sooner and snacking loses its pull.
- Interest has shifted from weight alone to what happens to the liver, because fatty liver disease travels with excess weight and often has no symptoms until it is advanced.
- Retatrutide specifically draws attention as a triple agonist (GLP-1, GIP and glucagon receptors), with the glucagon component hypothesised to act more directly on hepatic fat.
The evidence
What the research shows
- Semaglutide has the deepest evidence base: large randomised phase 3 trials over 68 weeks reported substantial mean weight reduction versus placebo, plus published cardiovascular and kidney outcome trials.
- Tirzepatide's dual-agonist trials reported larger mean weight reductions than earlier GLP-1-only programmes in head-to-head diabetes trials.
- Retatrutide's published phase 2 data reported the largest mean weight reductions of the class to date, alongside reductions in liver fat measured by imaging in a dedicated substudy. Phase 3 outcome data are not yet published, and it is not approved.
- Across the class, gastrointestinal side effects are the dominant reason people stop, and discontinuation is followed by substantial weight regain in published follow-up.
Reported use
How it is reported to be used
- The pattern reported in trial write-ups and clinic literature is a slow dose escalation over months rather than weeks, with nausea concentrated in the days after each increase.
- Weight loss without resistance training and adequate protein intake includes lean mass, which is why trial reporting increasingly separates fat mass from total mass.
- Liver fat improvements in published imaging substudies broadly tracked the amount of weight lost rather than appearing independent of it.
Our reading
Evidence verdict
BModerate Human EvidenceSeveral human trials exist, but they are limited in size, duration or consistency.
Strong for semaglutide and tirzepatide in approved indications; early but unusually promising for retatrutide, which remains investigational with no approved use.
Before you read further
Cautions and open questions
- None of these compounds is approved for use from a research-use-only source, and unapproved material has no verified identity, purity or concentration.
- Pancreatitis, gallbladder disease and severe dehydration from vomiting appear in the approved labels as risks requiring medical attention.
- Rapid loss without protein and resistance training costs lean mass; this is a documented trade-off, not a rumour.
Sources
Referenced research
- Phase 2 trial2023
Triple-hormone-receptor agonist retatrutide for obesity: phase 2 trial
New England Journal of Medicine- Main finding
- Reported dose-dependent mean body weight reduction over 48 weeks versus placebo.
- Randomised controlled trial2021
Once-weekly semaglutide in adults with overweight or obesity
New England Journal of Medicine- Main finding
- Reported mean weight reduction versus placebo over 68 weeks.
- Clinical trial
Registered interventional trials of incretin agonists
Educational content only. This page is not medical advice, a protocol or an individualised dosing recommendation. Reported use patterns summarise published literature and community reporting; they are not verified clinical cases and are not endorsements. Speak to a qualified healthcare professional about your own health.
All use cases